5,13 Vildagliptin is recommended at Step 2 for people with type 2 diabetes who are not eligible for funded SGLT-2 inhibitor or GLP-1 receptor agonist treatment (also see: Clinical scenarios where empagliflozin or dulaglutide are recommended, but not funded)
Oxalate typically exits your body via urine
This raises an important question about whether timing should evolve alongside innovation
As a class of drugs, GLP-1s have been shown to result in weight loss.[2] Common side effects of GLP-1s include nausea, vomiting, diarrhea, constipation, injection site reactions, headache, hypoglycemia, dyspepsia, fatigue, dizziness, abdominal pain, and gastroenteritis.[1-4] All GLP-1s carry a boxed warning for the risk of thyroid c-cell tumors and a contraindication for a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Once reconstituted, store at 4C and use within 30 days